By M. Will. University of Tennessee Health Science Center. 2019.
Transcribing medication orders is within the scope of practice for nurses and is part of the process of administering medication order nizagara 100 mg free shipping impotence problems. Guideline 13: When transcribing medication orders discount nizagara 25mg without prescription erectile dysfunction pills from canada, nurses apply professional judgment in deciding the administration schedule to maximize the therapeutic effect of the drug cheap 100 mg nizagara with amex erectile dysfunction young male causes, support client choice and comply with practice setting policy 50mg nizagara visa impotence cures. Electronic medication order entry systems allow prescribers to enter medication orders directly into the point of care electronic health record system. One of the benefits of electronic order entry systems is that errors related to illegible writing, incomplete orders or misunderstanding resulting from verbal and telephone orders are decreased. Nurses must know their role and responsibility in the transcribing of medication orders in an electronic order entry system as outlined by the employer. Guideline 14: Nurses are accountable for validating the accuracy and completeness of the transcription of the order before administering the medication to the client. Administering Medication The administration of medication is a cognitive and interactive aspect of nursing care and is more than the psychomotor task of administering a medication to a client. It involves client assessment, making clinical decisions and planning care based on this assessment and clinical data. Medication administration is performed in collaboration with the client and family. Infection Prevention and Control Practices Infection control practices and the prevention of disease transmission with medication administration are essential for client safety. Medication Preparation The preparation of medication is an important aspect of the medication administration process. Preparation can include selecting, calculating, mixing, labelling, drawing up and pouring. It is important for the same nurse to carry out all the steps of medication administration to decrease the risk of error and maintain clear lines of accountability. There may be situations where more than one health-care professional may be required to administer a single medication. These products are prepared, packaged, labelled and delivered to a client’s home and are ready to be administered by the nurse. Some medications are also pre-dosed directly from the drug manufacturer and are ready for administration to the client (e. In these situations, the nurse would need to be supported by practice setting policy and must document the nursing care they provided. Guideline 17: Nurses can administer pharmacy or manufacturer-prepared and labeled medications with an order from an authorized prescriber. Compounding Medication The definition of compound is: “compound” means to mix together two or more ingredients of which at least one is a drug for the purposes of dispensing a drug or drugs, but does not include reconstituting a drug or drugs with only water; (Government Organization Act. The mixing of medications of all dosage forms; oral liquid or solid, parenteral and topical often affects the storage requirements, stability, and subsequently the efficacy of the product. Consultation with a pharmacist and/or published references is expected if the nurse is mixing and/or storing compound medications. Drug delivery systems, complexity of care and workload can effect administering medication at the approved time. Nurses in all practice areas are encouraged to be involved in the development of practice setting guidelines or policies related to timely administration of scheduled medication. Client Consent Informed and capable clients have the right to make decisions about accepting or declining a medication or to self-administer medication. Nurses are responsible for ensuring that clients have accurate information about their medication in a format that the client can understand. Nurses respect client choice and verify informed consent with the client before administering a medication (Canadian Nurses Association, 2008). In a situation where a client refuses a medication, the nurse should determine the reasons; assess the client’s level of understanding about the medication’s effects, follow-up with the prescriber and document the situation. Informed consent can be recorded formally, such as on a consent form when a client is participating in a clinical trial. In clinical practice settings consent is given verbally or is implied; for example, a client holding out their arm for an injection. Policy and procedures for obtaining informed consent from the capable client should be developed and implemented based on legislation and best practices. Guideline 21: Nurses verify informed consent with the client before administering a medication. If they work together or influence the checking process by suggesting what the checker should find, both could follow the same path to an error. Some practice settings have established policy requiring nurses to perform independent double checks of certain high-risk medications such as insulin, heparin or chemotherapy. Guideline 22: Nurses follow practice setting policies and procedures for independent double checking of medication and document all aspects of their independent double check. Two Client Identifiers Proper identification of the client prior to medication administration is a safety process that can help eliminate the wrong medication being administered to a client (Accreditation Canada, 2013). The intent of checking at least two client identifiers is to reliably identify the individual as the person for whom the medication is intended and to match the medication label to that individual. The goal is to ensure accurate identification of care recipients and to ensure the safety of clients during medication administration. Range Doses Range doses are medication orders in which the dose, frequency or route of administration for a medication is prescribed in a range (e. Range doses are used in situations where a client’s need for the medication varies from day to day or within the same day. A range dose order gives the nurse the flexibility to make a decision on the appropriate dose of medication to administer, based on their assessment of the client immediately prior to medication administration. Orders for pain medication that contain a dosage range should have a fixed time interval (Gordon et al, 2004). Whenever possible, the nurse should have the client rate their pain using approved pain management tools, discuss with the client the appropriate amount of medication required, review the effectiveness of any previous medication dosages administered as a reference point, monitor and document the effectiveness of the medication administered. Problems can occur with range dose orders when clients are prescribed an exhaustive variety of pain management medication options in multiple routes and dosages without clear indications when to use which analgesic. In addition, problems can occur if the nurse considers using the unused dosage of a range dose order as a break-through pain order as this is not best practice. The nurse cannot administer another 1-2 mg of Morphine an hour later based on this same order as the order identifies the timeframe as q4h, not q1h. The nurse needs to contact the authorized prescriber for further medication orders to address the client’s pain. In the example provided above, the decision by the nurse to administer another 1-2 mg of Morphine is not permitted because of: the accountability and legal risk for the nurse acting outside of the timeframe of the Morphine order (the above order indicates that the client needs to wait at least three hours between doses) the lack of clarity on the time to administer the next prn dose of Morphine Clear communication among clients, nurses, physicians and pharmacists is vital for a range dose system to work effectively. Policy should address: which medication may be ordered and administered by means of a range dose order what type of range dose orders are appropriate (i. Prn Medications Prn medications are medications prescribed to be given only when a client requires it. A prn prescription includes the frequency with which the medication may be given, such as q4h prn. This time frame means that the client needs to wait at least four hours between doses. Nurses must not administer any prn medication for a purpose other than the one identified in the order. Allergy Testing and Desensitizing Injections Specialized knowledge, skill and judgment are required to administer allergy tests or desensitizing injections. Nurses who administer these agents should be supported by practice setting policy, as there may be a risk of sudden, severe side effects. Emergency equipment and resources should be readily available in the practice setting.
The production and sale of alcoholic beverages discount nizagara 25mg mastercard impotence in men over 50, together with the ancillary industries buy nizagara 50mg without a prescription impotence 36, are important 54 For a paired example see: ‘After the War on Drugs: Tools for the Debate’ order 100mg nizagara fast delivery erectile dysfunction treatment singapore, Transform Drug Policy Foundation buy 50 mg nizagara with visa injections for erectile dysfunction treatment, page 16, 2006. These economic and fiscal interests are often an important determinant of policies that can be seen as barriers to public health initiatives. Dissemination of public health research that can counterbalance these economic and fiscal interests is paramount. Alcohol producers and suppliers see alcohol from a commer- cial rather than a public health perspective. They do not bear the secondary costs of problematic alcohol use; quite naturally, their primary motivation is to generate the highest possible profits. This is logically achieved by maximising consumption, both in total popula- tion and per capita terms. Public health issues become a concern only when they threaten to impact on the bottom line, and will invariably be secondary to profit maximisation. They have achieved this by deploying a now familiar menu of high level lobbying, manufactured outrage and populist posturing (the ‘nanny state’ against ‘a man’s right to have a drink after work’ etc. In many countries these efforts have been highly effective at distracting from, or delaying, any meaningful regulatory legislation. In addition, they have often successfully kept what regulation has been passed at a voluntary level, meaning that it can largely be ignored or sidelined to the point of being almost completely ineffectual. Yet this is exactly what is required to address particular issues of binge and problem drinking, and to support the general evolution of a more moderate and responsible drinking culture. It is important to remember that problem- atic and binge drinking constitute a signifcant proportion of alcohol industry profts; they are, quite simply, hugely proftable consumer behaviours. Such concerns have prompted adoption of government monopoly control models for sections of alcohol supply in some coun- 57 tries. Examples include the Systembolaget system in Sweden, under which the state controls all import and supply, and the provincial government control of alcohol off-licences in some Canadian prov- inces (Ontario and Quebec). These models have some similarities to the Regulated Market Model proposed for tobacco (see: page 27). These factors combine with the immense lobbying power of alcohol industry bodies, and the public unpopularity of restricting alcohol sales or increasing prices, to create massive political obstacles to effective reforms. This is the case even when knowledge of what works from a public health perspective (that is, encouraging reduced and/or moderate consumption) is clear. In effect, many governments have been complicit in the growing public health crisis associated with alcohol. For alcohol policy to have an effective future it is clear that poten- tially very unpopular decisions will have to be made that will involve increasing regulation and heavy restrictions on all aspects of marketing and promotions. How such reforms unfold, combined with historic successes and failures in alcohol control, will continue to provide a rich resource for future, legally regulated markets to learn from. It is, however, associated with a disproportionate level of health harms, on a scale that eclipses all other drugs combined. These huge public health impacts are predominantly associated with smoked 58 tobacco; they are related to its high propensity to produce dependency, alongside the fact that it does not intoxicate to a degree that signifcantly impairs functioning. Many smokers consume nicotine more than 20 times every day, for prolonged periods—commonly over many years. Despite the high risks smoking presents (around half of smokers will die prematurely as a result of their use) the low level of intoxication created by nicotine has not historically attracted the moral indigna- tion that fuelled the temperance movement and shaped much punitive prohibitionist thinking on other drugs. As such, tobacco has assumed a unique role in society; a highly visible pattern of dependent drug use associated with a high risk of chronic health harms, yet one that 58 It has a rapid onset, a short half life, is associated with development of tolerance and distinct withdrawal effects and cravings—on top of psychological effects related to habituation into various personal and cultural consumption rituals. The public health disaster associated with smoked tobacco has, however, ultimately led to the emergence of a range of more pragmatic public health and regulatory responses in a number of countries. Like alcohol, the full gamut of policy responses to tobacco can be observed and learnt from, and there is a substantial body of related scholarship to be drawn upon. There is now a clear consensus around the types of interventions and market regulation that are likely to deliver improved policy outcomes. In stark contrast to those prohibited drugs, in the developed world, tobacco is becoming less, not more, popular; its use has been falling since the 1970s. The reining in of the rampant commercial marketing that fuelled the explosion of tobacco use (in particular of cigarettes) in the first half of the last century has been particularly important. Tobacco consumption is becoming more popular in large swathes of the devel- oping and newly industrialising world. In these areas, tobacco is being aggressively marketed, often as an aspirational Western lifestyle 107 1 2 3 Introduction Five models for regulating drug supply The practical detail of regulation product—somewhat ironic, given its waning popularity in the West. The commercial forces that have so effectively distorted policy priori- ties in the past have not lost any of their potential power. They sound a clear cautionary note on the corrupting nature of proft motivations in drug markets. In common with the regulatory/harm gradient theme explored in the previous chapters, there are public health gains to be had from exploring and developing the market for, and use of, safer, non-smoked nicotine/tobacco products, as alternatives to smoked tobacco. The increasing use of various nicotine delivery systems, (such as inhalers, gum and patches) as cessation aids is a welcome development, is already widespread, and should be actively supported. Such support could include increased access, as well as a reduction in price (subsidised where necessary) so that those most dependent on nicotine—in particular, those on low income—can afford to access these products. However, the use of nicotine delivery systems as cessation aids takes place within a medical model that is specifcally aimed at achieving abstinence. This is an important and proven part of the public health response to tobacco; it does not, however, cater for those who want to continue consuming nicotine, or will continue regardless of other interventions. Certain non-smoked oral tobacco products (including ‘Snus’ and ‘Bandits’) offer potential alternative tobacco preparation/consumption methods that are (it is estimated) 90% safer than smoked tobacco. This is despite a prohibitionist drug policy position that is, in most other respects, the most stringent in Europe. It has been convincingly argued that this high level of oral tobacco use correlates with the fact that the country has the lowest rate of smokers in the developed world. There has been a large drop in the number of smokers in Sweden, in particular within the male population—from 40% in 1976 to 15% in 2002—partially attributed to a roughly corresponding increased use of Snus. However, there is plenty of evidence from the Swedish model to suggest that Snus and other similar products can help users give up smoking, as well as providing a safer tobacco alternative. There are obviously diffcult ethical and practical questions regarding how such products can be brought to the market, and then regulated and promoted responsibly; that is, so as to encourage existing smokers to quit or switch from smoked tobacco, while not inducing a fresh tobacco consumption habit in new users. The potentially enormous public health gains are such that the relevant agencies should, on pragmatic public health grounds alone, seriously consider the options for appropriate legislative reforms. Research and pilot studies should be commissioned, as appropriate, to explore potential ways forward. Further reading * ‘50 Best Collection: Tobacco Harm Reduction’, International Harm Reduction Association, 2008 * R. It should also be acknowledged that the models proposed here refect the authors’ Western background. Other environments, and other user populations, will require different, regionally appropriate ways of thinking. In particular, we have highlighted potentials for greater or lesser levels of regulation, enforcement and/or deployment of additional controls. A large body of literature, research and real world experience can be drawn on to help plot out legal models for cannabis supply and use. Of particular relevance is the Netherlands’ experience with its unique ‘coffee shop’ system, a de facto legal licensing of supply and use that has been running since 1976. A primary issue is the so-called ‘back door problem’; that is, the fact that while both possession and supply from the coffee-shops is tolerated, with the former being effectively legal and the latter licensed, cannabis production itself remains illegal. This means that coffee shops are forced to source it from an illicit market 110 4 5 6 Making a regulated system happen Regulated drug markets in practice Appendices place. The fact that the Netherlands’ de facto legal supply is unique amongst its immediate geographic region has also caused problems of ‘drug tourism’ at its borders, with substantial numbers of buyers entering the country solely for procurement.
This actor may be implemented as the point of sale software of a community pharmacy or the hospital pharmacy module of a hospital information system cheap nizagara 100 mg without a prescription erectile dysfunction groups in mi. Description of the abstract repository-roles: • Medication Treatment Plan Repository 335 This repository contains the medication added to the patient’s plan from the Medication Treatment Planner and may receive updates to the current planning (cancelations order nizagara 50 mg with mastercard impotence 101, changes cheap nizagara 25mg with visa erectile dysfunction treatment bangkok, etc discount nizagara 50mg with mastercard erectile dysfunction injection drugs. It provides information about the planned medication to other actors such as the Community Pharmacy Manager. It provides information about the prescribed medication to other actors such as the Community Pharmacy Manager. It provides this information to other actors such as the Community Pharmacy Manager. It provides the dispensed medication of the patient to other actors such as the Community Pharmacy Manager. The 355 Administered Medication Repository provides the administered medication of the patient to other actors such as the Community Pharmacy Manager. Implementation scenarios in real-world projects will most likely differ from the topology of 360 having exactly three repositories. Querying actors may be: 375 • Medication Treatment Planner • Prescription Placer • Pharmaceutical Adviser • Medication Dispenser • Medication Administration Performer 380 This transaction provides a set of specialized queries: 17 Rev. These are: • FindMedicationTreatmentPlans (if “Medication Treatment Planning” Option is 385 supported) Find planned medication documents and their related documents • FindPrescriptions Find prescription documents and their related documents • FindDispenses 390 Find dispense documents and their related documents • FindMedicationAdministrations Find administered medication documents and their related documents • FindPrescriptionsForValidation Find prescriptions and their related documents containing Prescription Items ready to 395 be validated • FindPrescriptionsForDispense Find prescriptions and their related documents containing Prescription Items ready to be dispensed The last two queries can be parameterized to … 400 1. In this case the query returns all prescriptions which are in the requested status (e. In this model, generally speaking, information is generated by a placer type actor (Medication Treatment Planner, Prescription Placer, Pharmaceutical Adviser, Medication Dispenser or Medication Administration Performer) 485 and stored by means of a repository type actor. This approach may apply to health systems where information is accessed on a centralized basis and, therefore, is made available to a collective of potential users (such as prescriptions available for dispense in any community pharmacy). The alternative approach is the direct push model where information is sent directly to the actor 490 intended to use it (e. This model focuses on direct communication instead of availability to (more) potential users. The current revision of the Integration Profile covers use cases relying on the publish & pull model only. Note: The optional initial planning and the documentation of the administration of the medication would be eligible to be included in this scenario steps, but are not represented here in order to limit complexity. The practitioner examines John and prescribes the active substance 545 “Fenoterol” in his “Prescription Placer” software. Since prescriptions are available to a wide range of pharmacies, John picks the pharmacy closest to his office. The pharmacist asks for John’s health card in order to retrieve the patient’s active prescriptions. The information on the pharmaceutical advice is electronically sent to the “Pharmaceutical Advice Repository”. He consults his inventory and picks Berotec® which is in the range of prices approved by the health system. He gives out this medicine to the patient and records the transaction in the “Medication Dispenser”. The information on the medication dispensed is electronically sent to 555 the “Dispensed Medication Repository”. The physician examines John and decides to add John to a drug-substitution programme on Methadone. He adds “Methadone” to the planned medications in his “Medication Treatment Plan Planner” software. The new planned medication “Methadone” is electronically sent to the “Medication Treatment Plan Repository”. As a prescription is required for getting this medication from the pharmacy, the physician also 605 prescribes “10mg Methadone” as repeatable prescription in his “Prescription Placer” software. Regulations according to the drug-substitution therapy require the medication to be taken by the patient directly in the dispensing pharmacy so that the pharmacist witnesses the intake and is able to electronically document the administration. The patient drinks the Methadone solution in front of the pharmacist and the pharmacist documents the administration act in his “Medication Administration Performer” software. The documentation of the administration is electronically sent to the “Administered Medication 615 Repository”. This requires the support of the “Provision of Medication List” Option at the Community Pharmacy Manager. The practitioner examines John and wants to prescribe the active substance “Fenoterol” in his “Prescription Placer” software. To ensure that there are no conflicts between the new medication and the patient’s current medication status, the physician requests the Medication List. The Community Pharmacy Manager queries the registry for the on-demand document entry of the Medication List to this patient. Either the found or just created Document Entry will be returned to the calling Prescription Placer. Once the document is assembled it returns the document to the calling Prescription Placer. If the “Persistence of Retrieved Documents” Option is used the returned document is also provided and registered in 650 the registry/repository backend. The physician performs another physical examination to confirm the improved health status and decides to amend the treatment with Fenoterol by either changing it (e. The physician issues a Community Pharmaceutical Advice document to record the command and instructs the patient. After getting a chemotherapy medication administered by a nurse and the administration act was fully documented, the patient goes home, but since he felt very bad, she returns to the outpatient department of the hospital and faints while waiting for her oncologist. After arrival, the oncologist performs a physical examination and recognizes a potential relation 710 of this issue to the just administered chemotherapy medication. The oncologist issues a Community Pharmaceutical Advice document related to the documented administration to document this potential medication-related issue. The planning, prescription and dispense process of real-world projects involves several parties acting in the different abstract roles (Medication Treatment Planner, Prescription Placer, Pharmaceutical Adviser, Medication Dispenser, Medication Administration Performer). The Medication Treatment Planner and Prescription Placer roles are usually taken by physicians; the 730 Pharmaceutical Adviser and Medication Dispenser role is usually taken by pharmacists; the Medication Administration Performer role may be taken by physicians or nurses, which all are usually organized in different organizations. This results in a wide variety of implementation requirements together with the need of not only organizational but also technical separation of systems. Physicians may want to store plans, 735 prescriptions and administrations in another repository other than where pharmacists store dispenses or nurses store administrations. Any political intended separation has to be technically bridged at one point otherwise a common 740 planning, prescription and dispense process cannot be established. To minimize the possible points of contact between the domains the Community Pharmacy Manager was introduced. On the other hand a simple scenario like this may not be applicable to scenarios in reality, where organizational, strategical or political reasons require more separation between the participating parties (physicians, pharmacists). Note: The “Administration” level (Medication Administration Performer) aligns with the principle as shown and is not included in this scenario in the interest of simplicity. Group of Medication Group of Pharmaceutical Treatment Plan Placers Advisers Community Pharmacy Pharmaceutical Manager Pharmaceuticaladvicer Medication Pharmaceuticaladvicer Pharm. Plan Medication Repository Plan PlacerTreatment Planner Group of Prescription Placers Dispnser Prescription Dispenser Prescriptionplacer Medication Disp.
Pulmonary auscultation is often normal nizagara 50 mg otc erectile dysfunction what age does it start; sometimes dullness indicating pleural effusion safe 50mg nizagara herbal erectile dysfunction pills uk. Clinical evolution – There is a serious risk of decompensation from pneumothorax or suppurative pleurisy or pyopneumothorax quality 100 mg nizagara causes of erectile dysfunction in 40 year old. These episodes are usually associated with airflow obstruction within the lung generic 25mg nizagara visa erectile dysfunction 21, often reversible, either spontaneously or with treatment. Factors that precipitate/aggravate asthma include: allergens, infection, exercise, drugs (aspirin), tobacco, etc. In young children, most initial episodes of asthma-like symptoms are associated with a respiratory tract infection, with no symptoms between infections. Wheezing episodes usually become less frequent with time; most of these children do not develop asthma. Asthma attack (acute asthma) Asthma attack is a substantial worsening of asthma symptoms. Assessment of the severity of asthma attack The severity of the asthma attack must be rapidly evaluated by the following clinical criteria. In children, use a spacera to ease administration (use face mask in children under 3 years). Single puffs should be given one at a time, let the child breathe 4 to 5 times from the spacer before repeating the procedure. Reassess after 10 days: consider long-term treatment if the asthma attacks have been occurring for several months. If the patient is already receiving long-term treatment, reassess the severity of the asthma (see table page 83) and review compliance and correct use of medication and adjust treatment if necessary. The child breathes from the mouth of the bottle in the same way as he would with a spacer. In mild or moderate asthma attacks, administering oxygen reduces the risk of foetal hypoxia. Chronic asthma Clinical features – Asthma should be suspected in patients with episodic respiratory symptoms (wheezing, chest tightness, shortness of breath and/or cough) of variable frequency, severity and duration, disturbing sleep, and causing the patient to sit up to breathe. Patients with typical symptoms of asthma and a history of disease that is characteristic of asthma should be considered as having asthma after exclusion of other diagnoses. The assessment of the frequency of daytime and nigthtime symptoms and limitations of physical activity determines whether asthma is intermittent or persistent. Treatment is started at the step most appropriate to initial severity then, re-evaluated and adjusted according to clinical response. It aims to abolish symptoms with the lowest possible dose of inhaled corticosteroids. An intervening severe exacerbation or loss of control necessitates reassessment to re-evaluate treatment. Asthma attacks may occur over months or years, with intervening asymptomatic intervals when long-term treatment is not required. Long-term treatment of asthma according to severity Categories Treatment Intermittent asthma No long term treatment • Intermittent symptoms (< once/week) Inhaled salbutamol when symptomatic • Night time symptoms < twice/month • Normal physical activity Mild persistent asthma Continuous treatment with inhaled beclometasone • Symptoms > once/week, but < once/day + • Night time symptoms > twice/month Inhaled salbutamol when symptomatic • Symptoms may affect activity Moderate persistent asthma Continuous treatment with inhaled beclometasone • Daily symptoms + • Symptoms affect activity Inhaled salbutamol (1 puff 4 times/day) • Night time symptoms > once/week • Daily use of salbutamol Severe persistent asthma Continuous treatment with inhaled beclometasone • Daily symptoms + • Frequent night time symptoms Inhaled salbutamol (1-2 puff/s 4 to 6 times/day) • Physical activity limited by symptoms Inhaled corticosteroid treatment: beclometasone dose varies according to the severity of asthma. Find the minimum dose necessary to both control the symptoms and avoid local and systemic adverse effects: Children: 50 to 100 micrograms twice daily depending on the severity. In patients with severe chronic asthma the dosage may be as high as 800 micrograms/day. Adults: start with 250 to 500 micrograms twice daily depending on to the severity. If a total dosage of 1000 micrograms/day (in 2 to 4 divided doses) is ineffective, the dosage may be increased to 1500 micrograms/day, but the benefits are limited. The number of puffs of beclometasone depends on its concentration in the inhaled aerosol: 50, 100 or 250 micrograms/puff. If exercise is a trigger for asthma attacks, administer 1 or 2 puffs of salbutamol 10 minutes beforehand. In pregnant women, poorly controlled asthma increases the risk of pre-eclampsia, eclampsia, haemorrhage, in utero growth retardation, premature delivery, neonatal hypoxia and perinatal mortality. Long-term treatment remains inhaled salbutamol and beclometasone at the usual dosage for adults. If symptoms are not well controlled during a period of at least 3 months, check the inhalation technique and adherence before changing to a stronger treatment. If symptoms are well controlled for a period of at least 3 months (the patient is asymptomatic or the asthma has become intermittent): try a step-wise reduction in medication, finally discontinuing treatment, if it seems possible. If the patient has redeveloped chronic asthma, restart long-term treatment, adjusting doses, as required. In immunocompetent patients, the pulmonary lesion heals in 90% of cases, but in 10%, patients develop active tuberculosis. Tuberculosis may also be extrapulmonary: tuberculous meningitis, disseminated tuberculosis, lymph node tuberculosis, spinal tuberculosis, etc. Clinical features Prolonged cough (> two weeks), sputum production, chest pain, weight loss, anorexia, fatigue, moderate fever, and night sweats. The most characteristic sign is haemoptysis (presence of blood in sputum), however it is not always present and haemoptysis is not always due to tuberculosis. If sputum is smear-negative, consider pulmonary distomatosis (Flukes, Chapter 6), melioidosis (Southeast Asia), profound mycosis or bronchial carcinoma. In an endemic area, the diagnosis of tuberculosis is to be considered, in practice, for all patients consulting for respiratory symptoms for over two weeks who do not respond to non-specific antibacterial treatment. Treatment The treatment is a combination of several of the following antituberculous drugs [isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), streptomycin (S)]. The regimen is standardised and organized into 2 phases (initial phase and continuation phase). Only uninterrupted treatment for several months may lead to cure and prevent the development of resistance, which complicates later treatment. It is essential that the patient understands the importance of treatment adherence and that he has access to correct case management until treatment is completed. Diseases, such as malaria, acute otitis media, upper and lower respiratory tract infections, etc. Treatment General principles: – Prevent or treat dehydration: rehydration consists of prompt replacement of fluid and electrolyte losses as required, until the diarrhoea stops. However, for treating cholera, the administration of a single dose should not provoke any adverse effects. Bloody diarrhoea (dysentery) – Shigellosis is the most frequent cause of dysentery (amoebic dysentery is much less common). If there is no laboratory diagnosis to confirm the presence of amoebae, first line treatment is for shigellosis. Prevention – Breastfeeding reduces infant morbidity and mortality from diarrhoea and the severity of diarrhoea episodes. Shigella dysenteriae type 1 (Sd1) is the only strain that causes large scale epidemics. Clinical features Bloody diarrhoea with or without fever, abdominal pain and tenesmus, which is often intense. Patients with at least one of the following criteria have an increased risk of death: – Signs of serious illness: • fever > 38. After confirming the causal agent, antimicrobial susceptibility should be monitored monthly by culture and sensitivity tests. Organise home visits for daily monitoring (clinically and for compliance); hospitalise if the patient develops signs of serious illness. Shigellosis is an extremely contagious disease (the ingestion of 10 bacteria is infective). Note: over the past few years, Sd1 epidemics of smaller scale and with lower case fatality rates (less than 1%) have been observed.
Use a nasogastric tube for a few days if pain is preventing the patient from eating buy cheap nizagara 50 mg on-line erectile dysfunction natural treatment options. Oral and oropharyngeal candidiasis Infection due to Candida albicans buy nizagara 25 mg lowest price erectile dysfunction causes diabetes, common in infants nizagara 25mg erectile dysfunction medication new zealand, immunocompromised or diabetic patients purchase 50 mg nizagara free shipping erectile dysfunction how common. Other risk factors include treatment with oral antibiotics or high-dose inhaled corticosteroids. Clinical features White patches on the tongue, inside the cheeks, that may spread to the pharynx. Show the mother how to treat since, in most cases, candidiasis will be treated at home. Primary infection typically occurs in children aged 6 months-5 years and may cause acute gingivostomatitis, sometimes severe. After primary infection, the virus remains in the body and causes in some individuals periodic recurrences which are usually benign (herpes labialis). Local lesions are usually associated with general malaise, regional lymphadenopathy and fever. Both forms of herpes are contagious: do not touch lesions (or wash hands afterwards); avoid oral contact. Other infectious causes See Pharyngitis (Chapter 2), Diphtheria (Chapter 2), Measles (Chapter 8). It is common in contexts of poor food quality or in populations completely dependent on food aid (refugee camps). Other lesions resulting from a nutritional deficiency Other vitamin deficiencies may provoke mouth lesions: angular stomatitis of the lips and glossitis from vitamin B2 (riboflavin), niacin (see Pellagra, Chapter 4) or vitamin B6 (pyridoxine) deficiencies. They must be treated individually or collectively, but must also be considered as indicators of the sanitary condition of a population. A high prevalence of infectious skin diseases may reflect a problem of insufficient water quantity and lack of hygiene in a population. Dermatological examination 4 – Observe the type of lesion: • Macule: flat, non palpable lesion that is different in colour than the surrounding skin • Papule: small (< 1 cm) slightly elevated, circumscribed, solid lesion • Vesicle (< 1 cm), bulla (> 1 cm): clear fluid-filled blisters • Pustule: vesicle containing pus • Nodule: firm, elevated palpable lesion (> 1 cm) that extend into the dermis or subcutaneous tissue • Erosion: loss of the epidermis that heals without leaving a scar • Excoriation: erosion caused by scratching • Ulcer: loss of the epidermis and at least part of the dermis that leaves a scar • Scale: flake of epidermis that detaches from the skin surface • Crust: dried serum, blood, or pus on the skin surface • Atrophy: thinning of the skin • Lichenification: thickening of the skin with accentuation of normal skin markings – Look at the distribution of the lesions over the body; observe their arrangement: isolated, clustered, linear, annular (in a ring). At this stage, primary lesions and specific signs may be masked by secondary infection. In these cases, it is necessary to re-examine the patient, after treating the secondary infection, in order to identify and treat the underlying skin disease. It exists in two forms: ordinary scabies, relatively benign and moderately contagious; and crusted scabies, favoured by immune deficiency, extremely contagious and refractory to conventional treatment. Person to person transmission takes place chiefly through direct skin contact, and sometimes by indirect contact (sharing clothing, bedding). The challenge in management is that it must include simultaneous treatment of both the patient and close contacts, and at the same time, decontamination of clothing and bedding of all persons undergoing treatment, in order to break the transmission cycle. Clinical features Ordinary scabies In older children and adults – Itching, worse at night, very suggestive of scabies if close contacts have the same symptom and – Typical skin lesions: • Scabies burrows (common): fine wavy lines of 5 to 15 mm, corresponding to the tunnels made by the parasite within the skin. Burrows are most often seen in the interdigital spaces of the hand and flexor aspect of the wrist, but may be present on the areolae, buttocks, elbows, axillae. Burrows may be associated with vesicles, corresponding to the entry point of the parasite in the skin. Typical lesions and secondary lesions may co-exist, or specific lesions may be entirely masked by secondary lesions. In infants and young children – Vesicular eruption; often involving palms and soles, back, face, and limbs. Crusted (Norwegian) scabies Thick, scaly, erythematous plaques, generalised or localised, resembling psoriasis, with or without itching (50% of cases). They are washed at ≥ 60°C then dried in the sun, or exposed to sunlight for 72 hours, or sealed in a plastic bag for 72 hours. Ordinary scabies Topical treatment 4 Topical scabicides are applied over the entire body (including the scalp, post-auricular areas, umbilicus, palms and soles), avoiding mucous membranes and face, and the breasts in breastfeeding women. The recommended contact time should not be shortened or exceeded; the patient must not wash his hands while the product is in use (or the product should be reapplied if the hands are washed). In infants, the hands must be wrapped to prevent accidental ingestion of the product. Treatment of secondary bacterial infection, if present, should be initiated 24 to 48 hours before use of topical scabicides (see Impetigo). The preferred treatment is 5% permethrin (lotion or cream): Child > 2 months and adult: one application, with a contact time of 8 hours, then rinse off. Permethrin is easier to use (no dilution required), and preferred over benzyl benzoate in children, and pregnant/lactating women. One application may be sufficient, but a second application 7 days later reduces the risk of treatment failure. A single dose may be sufficient; a second dose 7 days later reduces the risk of treatment failure. Persistence of typical burrows beyond 3 weeks should lead to suspicion of treatment failure (insufficient treatment, e. Crusted scabies Treatment combines simultaneous administration of oral ivermectin and topical scabicide at regular intervals, e. Crusts should be softened (salicylic acid ointment) and removed before applying local treatment (otherwise, local treatment is ineffective). As exfoliated skin scales may spread the parasite, the patient should be isolated during the treatment, staff should use protection (gloves, gowns and hand washing after contact), and environment (bedding, floors and surfaces) should be decontaminated. Body lice are potential vectors of relapsing fever (Chapter 7), typhus (Eruptive rickettsioses, Chapter 7) and trench fever. Treatment Head lice Apply to dry hair 1% permethrin lotion (leave on for 10 min) or 0. Decontaminate combs, headwear and bedding (wash ≥ 60°C/30 min, iron or dry in the sun or, if not feasible, seal in a plastic bag for 2 weeks). Treat those contacts with lice and/or live nits, not those with dead nits alone (dull, white, > 1 cm from scalp) as above. Body lice Mass treatment (outbreakk) Apply 30 to 60 g (2 to 4 heaped soup spoons) of 0. Individual treatment Disinfection of clothing and bedding as above or as for head lice. Treatment of secondary bacterial infection, if present, should begin 24 to 48 hours before local antiparasitic treatment (see Impetigo); local treatment is applied later when tolerated. Clinical features and treatment 4 Candidiasis Candidal diaper dermatitis Erythema of the perianal area with peripheral desquamation and sometimes pustules. Other candidiasis – Candidiasis of skin folds: miconazole 2% cream, twice daily for 2 to 4 weeks – Oral candidiasis: see Stomatitis, Chapter 3. Dermatophytoses Dermatophytes cause various clinical lesions, depending on the anatomic site involved: scalp, glabrous (hairless) skin, folds or nails. Scalp ringworm Depending on the species: • Local treatment: 2 times/day, clean with soap and water, dry and apply miconazole 2% Tinea capitis • One or more round, scaly, erythematous cream or Whitfield’s ointment for 2 weeks or longer if necessary. Adults: 200 mg once daily for 2 to 4 weeks • Suppurative lesions: treat superinfection (see Impetigo) before applying local antifungal treatment. Apply a topical treatment (miconazole 2% cream or Whitfield’s ointment) to limit the spread of infection until it is possible to treat orally. Glabrous skin Erythematous, scaly, pruritic macule with a well- • For non widespread, localised tinea: Ringworm of the demarcated, raised, vesicular border and central Local treatment: 2 times/day, clean with soap and water, dry and apply miconazole 2% body healing. If oozing lesions, use miconazole 2% cream only (do not use Tinea pedis Pruritus, fissure and whitish scales in the 3rd Whitfield’s ointment). Treatment is prolonged (12 to 18 months with griseofulvin) thus, in practice, difficult.
8 of 10 - Review by M. Will
Votes: 80 votes
Total customer reviews: 80